ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
Serum Mucin-1 (CA15-3) in Relation to Pulse Pressure Amplification in Untreated Chinese Patients.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mucin-1 was reported be correlated with organ fibrosis. Pulse pressure amplification (PPA) was a marker of arterial stiffness. We investigate the association of serum mucin-1 (CA15-3) concentration with peripheral and central blood pressure and PPA in untreated Chinese patients. The study participants were outpatients who were suspected of hypertension, but had not been treated with antihypertensive medication for at least two weeks. Serum mucin-1 (CA15-3) concentration was measured by the enzyme-linked immunosorbent assay method. PPA was the brachial-to-aortic pulse pressure ratio. The 1761 participants included 916 (52.0%) women, and 578 (32.8%) participants with clinic hypertension. Mean (±standard deviation [SD]) age was 51.3±10.6 years. After adjustment for confounders, higher serum mucin-1 (CA15-3) concentration was significantly associated with higher peripheral and central systolic and diastolic blood pressure (p≤0.009) and lower PPA (p = 0.037). Among 428 participants with a PPA equal or greater than 130% at baseline, 185 progressed to be a lower PPA (<130%) during a median follow-up of 4.65 years. Hazard ratio expressed the relative risk of lower PPA per 1 SD increment in the log transformed serum mucin-1 (CA15-3) concentration was 1.22 (p = 0.027). In women but not in men, the risk of lower PPA was significantly higher with increased baseline serum mucin-1 (CA15-3) concentration (p for interaction 0.015). Higher circulating mucin-1 (CA15-3) concentration was independently associated with higher peripheral and central blood pressure and lower PPA in untreated Chinese patients. It also correlated with the progression of arterial stiffness as indicated by a lower PPA, especially in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.